Committee approvals guarantee induced profits and increase number of investors

Written by Alyssa Clark Surprisingly, the basis of a persons or companys reputation still stands firmly on its public appeal— and that can go a ...

Admin
|Nov 26|magazine7 min read

Written by Alyssa Clark

 

Surprisingly, the basis of a person’s or company’s reputation still stands firmly on its public appeal— and that can go a long way for a business. Being well-received by the public, as well as gaining the respect and approval of the notable industry-committees gains public trust, challenges company-competitors to hit the same standards and produces and inherent amount of pride and respect for the institution who earns such accreditation. Investors are not ones to look away from a company being escorted into the lime-light by the CHMP, earning the respect from these institutions is a sure way to attract pocket-lined healthcare investors looking for a stable and safe investment.

The endorsement from healthcare committees like CHMP, the FDA and others can go a long way in igniting and promoting the success of various healthcare companies, as we have recently seen in the media with companies like Celgene Corporation; it can even go as far as to increase stock prices, product sales and overall company growth— go figure. By gaining the trust and public support from some of the most influential healthcare committees in the business today, not only does the public feel more secure in trusting the products of an endorsed-company, but the sales has that reliable source to use in its advertising and marketing initiatives.

Companies like Celgene Corporation have recently learned this lesson and are enjoying the spotlight, by seeing the literal pay-off one can experience if investing in and earning sponsorship from CHMP (Committee for Medicinal Products for Human Use) and a positive opinion of the EMA (European Medicines Agency). Subsequently, the company experienced a 52-week high of $164.00 on November 22, 2013, after its cancer drug Abraxane was reviewed with glowing recommendations by both institutions. After first receiving the approval of the FDA as of last year, the accompaniment of the CHMP’s approval has set Celgene up to be a serious contender in the cancer-drug research and production aspect of the business.

“We note that Abraxane is already available in the EU as a monotherapy for treating adults suffering from metastatic breast cancer. The patients have failed first-line therapy for metastatic disease. Moreover, standard, anthracycline containing treatment is not indicated in those patients. We note that Abraxane is approved in more than 40 countries across the globe for the metastatic breast cancer indication’, says Zacks Equity research, about the success of Celgene Corp.’s cancer drug and the corporation’s expansion.

Next on the list of approvals for Celgene is the European Commission (EC), now that the drug is 100 percent cleared for first-line combination therapy for treating patients suffering from locally advanced or metastatic non-small cell lung cancer. Setting standards high by earning these industry-wide accreditations, and having the success Abraxane speak for itself, Celgene Corporation has embraced the screening process and used it to its full advantage. The pay offs from the 52-week high alone proves the importance of investing in meeting quality standards, and earning the necessary approvals from widely-respected government agencies can go a long way in improving a business model and attracting investors.